{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T12:09:24Z","timestamp":1775304564509,"version":"3.50.1"},"reference-count":68,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1097\/wco.0b013e32834916a9","type":"journal-article","created":{"date-parts":[[2011,7,4]],"date-time":"2011-07-04T11:20:25Z","timestamp":1309778425000},"page":"497-503","source":"Crossref","is-referenced-by-count":43,"title":["Amyotrophic lateral sclerosis"],"prefix":"10.1097","volume":"24","author":[{"given":"Mamede","family":"de Carvalho","sequence":"first","affiliation":[]},{"given":"Michael","family":"Swash","sequence":"additional","affiliation":[]}],"member":"276","reference":[{"issue":"Suppl","key":"R1-14-20210206","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/0022-510X(94)90191-0","article-title":"El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis.","volume":"124","author":"Brooks","year":"1994","journal-title":"J Neurol Sci"},{"key":"R2-14-20210206","first-page":"293","article-title":"for the World Federation of Neurology Research Committee on Motor Neuron DiseasesEl Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis.","volume":"1","author":"Brooks","year":"2000","journal-title":"Amyotroph Lateral Scler"},{"key":"R3-14-20210206","first-page":"1292","article-title":"Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria.","volume":"49","author":"Traynor","year":"1997","journal-title":"Arch Neurol"},{"key":"R4-14-20210206","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.clinph.2007.09.143","article-title":"Electrodiagnostic criteria for the diagnosis of ALS.","volume":"119","author":"de Carvalho","year":"2008","journal-title":"Clin Neurophysiol"},{"key":"R5-14-20210206","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/17482960802521126","article-title":"Awaji diagnostic algorithm increases sensitivity of El Escorial criteria for ALS diagnosis.","volume":"10","author":"de Carvalho","year":"2009","journal-title":"Amyotroph Lateral Scler"},{"key":"R6-14-20210206","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3109\/17482961003777462","article-title":"Sensitivity and specificity of the Awaji electrodiagnostic criteria for amyotrophic lateral sclerosis: retrospective comparison of the Awaji and revised El Escorial criteria for ALS.","volume":"11","author":"Boekestein","year":"2010","journal-title":"Amyotroph Lateral Scler"},{"key":"R7-14-20210206","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1136\/jnnp.2009.197434","article-title":"An evaluation of neurophysiological criteria used in the diagnosis of motor neuron disease.","volume":"81","author":"Douglass","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R8-14-20210206","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/mus.21841","article-title":"Experience with the Awaji island modifications to the ALS diagnostic criteria.","volume":"42","author":"Chen","year":"2010","journal-title":"Muscle Nerve"},{"key":"R9-14-20210206","first-page":"29","article-title":"Can Awaji criteria provide earlier diagnosis than the revised El Escorial criteria J Neurol S","volume":"302","author":"Okita","year":"2011","journal-title":"ci"},{"key":"R11-14-20210206","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.clinph.2010.06.027","article-title":"Lower motor neuron involvement examined by quantitative electromyography in amyotrophic lateral sclerosis.","volume":"122","author":"Krarup","year":"2011","journal-title":"Clin Neurophysiol"},{"key":"R12-14-20210206","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/jnnp.2009.186833","article-title":"Detecting fasciculations in amyotrophic lateral sclerosis: duration of observation required.","volume":"82","author":"Mills","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R13-14-20210206","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1093\/brain\/awq290","article-title":"Characteristics of fasciculations in amyotrophic lateral sclerosis and the benign fasciculation syndrome.","volume":"133","author":"Mills","year":"2010","journal-title":"Brain"},{"key":"R14-14-20210206","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17482960802585469","article-title":"Genetic studies of amyotrophic lateral sclerosis: controversies and perspectives.","volume":"10","author":"Beleza-Meireles","year":"2009","journal-title":"Amyotroph Lateraleral Scler"},{"key":"R15-14-20210206","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/ng1123","article-title":"Mutant dynactin in motor neuron disease.","volume":"33","author":"Puls","year":"2003","journal-title":"Nat Genet"},{"key":"R16-14-20210206","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1093\/hmg\/3.10.1757","article-title":"Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis.","volume":"3","author":"Figlewiccz","year":"1994","journal-title":"Hum Mol Genet"},{"key":"R17-14-20210206","doi-asserted-by":"crossref","first-page":"552e1","DOI":"10.1016\/j.neurobiolaging.2010.02.011","article-title":"A novel peripherin gene (PRPH) mutation identified in one sporadic amyotrophic lateral sclerosis patient.","volume":"32","author":"Corrado","year":"2011","journal-title":"Neurobiol Aging"},{"key":"R18-14-20210206","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1126\/science.1134108","article-title":"Ubiquitinated TDP-43 in fronto-temporal lobar degeneration and amyotrophic lateral sclerosis.","volume":"314","author":"Neumann","year":"2006","journal-title":"Science"},{"key":"R19-14-20210206","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1126\/science.1154584","article-title":"TDP-43 mutations in familial amyotrophic lateral sclerosis.","volume":"319","author":"Sreedharan","year":"2008","journal-title":"Science"},{"key":"R20-14-20210206","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ana.21147","article-title":"Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations.","volume":"6","author":"Mackenzie","year":"2007","journal-title":"Ann Neurol"},{"key":"R21-14-20210206","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1083\/jcb.200908164","article-title":"Noncell autonomous toxicity in neurodegenerative disorders: ALS and beyond.","volume":"187","author":"Ilieva","year":"2009","journal-title":"J Cell Biol"},{"key":"R22-14-20210206","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1038\/nn.2660","article-title":"Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS.","volume":"13","author":"Bosco","year":"2010","journal-title":"Nat Neurosci"},{"key":"R23-14-20210206","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1172\/JCI44867","article-title":"Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice.","volume":"1","author":"Igaz","year":"2011","journal-title":"J Clin Invest"},{"key":"R24-14-20210206","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1001\/archneurol.2010.352","article-title":"Large proportion of amyotrophic lateral sclerosis cases in Sardinia due to a single founder mutation of the TARDP gene.","volume":"68","author":"Chio","year":"2011","journal-title":"Arch Neurol"},{"key":"R25-14-20210206","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.1165942","article-title":"Mutations in FUS, and RNA processing protein cause familial amyotrophic lateral sclerosis type 6.","volume":"323","author":"Vance","year":"2009","journal-title":"Science"},{"key":"R26-14-20210206","first-page":"323","article-title":"Young sporadic amyotrophic lateral sclerosis: a distinct nosological entity Amyotroph Lateral S","volume":"8","author":"Gouveia","year":"2007","journal-title":"cler"},{"key":"R27-14-20210206","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1212\/WNL.0b013e3181ed9cde","article-title":"Juvenile ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations.","volume":"75","author":"Baumer","year":"2010","journal-title":"Neurology"},{"key":"R28-14-20210206","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00401-010-0698-6","article-title":"FUS pathology defined the majority of tau- and TDP-43-negative frontotemporal lobar degeneration.","volume":"120","author":"Urwin","year":"2010","journal-title":"Acta Neuropathol"},{"key":"R30-14-20210206","doi-asserted-by":"crossref","first-page":"R46","DOI":"10.1093\/hmg\/ddq137","article-title":"TDP-43 and FUSTLS: emerging roles in RNA processing and neurodegeneration.","volume":"19","author":"Lagier-Tourenne, Polymenidou","year":"2010","journal-title":"Hum Mol Gen"},{"key":"R31-14-20210206","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature09320","article-title":"Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS.","volume":"466","author":"Elden","year":"2010","journal-title":"Nature"},{"key":"R32-14-20210206","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1093\/hmg\/ddr045","article-title":"Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients.","volume":"20","author":"Lee","year":"2011","journal-title":"Hum Mol Genet"},{"key":"R33-14-20210206","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/ana.21993","article-title":"Paraoxonase gene mutations in amyotrophic lateral sclerosis.","volume":"68","author":"Ticozzi","year":"2010","journal-title":"Ann Neurol"},{"key":"R34-14-20210206","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/jnnp.2010.212225","article-title":"Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review.","volume":"82","author":"Seelar","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R35-14-20210206","first-page":"1094","article-title":"Are amyotrophic lateral sclerosis patients cognitively normal N","volume":"60","author":"Lomen-Hoerth","year":"2003","journal-title":"eurology"},{"key":"R36-14-20210206","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1212\/01.wnl.0000188759.87240.8b","article-title":"The effects of executive dysfunction on the course of ALS.","volume":"65","author":"Olney","year":"2005","journal-title":"Neurology"},{"key":"R37-14-20210206","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1212\/WNL.0b013e318214359f","article-title":"Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia.","volume":"76","author":"Elamin","year":"2011","journal-title":"Neurology"},{"key":"R39-14-20210206","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.neuron.2010.11.036","article-title":"Exome sequencing reveals VCP mutations as a cause of familial ALS.","volume":"68","author":"Johnson","year":"2010","journal-title":"Neuron"},{"key":"R40-14-20210206","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1474-4422(10)70197-6","article-title":"Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study.","volume":"10","author":"Shatunov","year":"2010","journal-title":"Lancet Neurol"},{"key":"R41-14-20210206","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1474-4422(10)70184-8","article-title":"Chromosome 9p21in amyotrophic lateral sclerosis in Finland: a genomewide association study.","volume":"9","author":"Laaksovirta","year":"2010","journal-title":"Lancet Neurol"},{"key":"R42-14-20210206","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/NEN.0b013e3181ee7d85","article-title":"TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy.","volume":"69","author":"McKee","year":"2010","journal-title":"J Neuropathol Exp Neurol"},{"key":"R43-14-20210206","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1212\/WNL.0b013e3181d5dc3b","article-title":"CSF glial markers correlate with survival in in amyotrophic lateral sclerosis.","volume":"74","author":"Sussmuth","year":"2010","journal-title":"Neurology"},{"key":"R45-14-20210206","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/mus.21625","article-title":"Plasma biomarkers associated with ALS and their relationship to iron homeostasis.","volume":"42","author":"Mitchell","year":"2010","journal-title":"Muscle Nerve"},{"key":"R46-14-20210206","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/mus.21683","article-title":"Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics.","volume":"42","author":"Ryberg","year":"2010","journal-title":"Muscle Nerve"},{"key":"R47-14-20210206","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.brainres.2010.09.033","article-title":"Quantification of cystatin C in cerebrospinal fluid from various neurological disorders and correlation with G73A polymorphism in CST3.","volume":"1361","author":"Yamamoto-Watanabe","year":"2010","journal-title":"Brain Res"},{"key":"R48-14-20210206","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1471-4159.2011.07224.x","article-title":"Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS.","volume":"117","author":"Ganesalingam","year":"2011","journal-title":"J Neurochem"},{"key":"R49-14-20210206","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1001\/archneur.65.11.1481","article-title":"TDP-43 in cerebrospinal fluid of patients with fronto-temporal lobar degeneration and amyotrophic lateral sclerosis.","volume":"65","author":"Steinacker","year":"2008","journal-title":"Arch Neurol"},{"key":"R50-14-20210206","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1093\/brain\/awl172","article-title":"Novel threshold tracking techniques suggest that cortical excitability is an early feature of motor neuron disease.","volume":"129","author":"Vucic","year":"2006","journal-title":"Brain"},{"key":"R51-14-20210206","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.clinph.2010.02.164","article-title":"Corticomotoneuronal function in asymptomatic SOD-1 mutation carriers.","volume":"121","author":"Vucic","year":"2010","journal-title":"Clin Neurophysiol"},{"key":"R52-14-20210206","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.clinph.2009.02.170","article-title":"Predicting respiratory insufficiency in amyotrophic lateral sclerosis: the role of phrenic nerve studies.","volume":"120","author":"Pinto","year":"2009","journal-title":"Clin Neurophysiol"},{"key":"R53-14-20210206","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.clinph.2009.08.025","article-title":"Changes of the phrenic nerve motor response in amyotrophic lateral sclerosis.","volume":"120","author":"Pinto","year":"2010","journal-title":"Clin Neurophysiol"},{"key":"R54-14-20210206","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1212\/01.WNL.0000162036.76024.AB","article-title":"Quantitating progression in ALS.","volume":"24","author":"de Carvalho","year":"2005","journal-title":"Neurology"},{"key":"R55-14-20210206","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/17482968.2010.531742","article-title":"Neurophysiological index as a biomarker for ALS progression: validity of mixed effect models.","volume":"12","author":"Cheah","year":"2011","journal-title":"Amyotroph Lateral Scler"},{"key":"R56-14-20210206","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/CND.0b013e3181934423","article-title":"Localized muscle impedance abnormalities in amyotrophic lateral sclerosis.","volume":"10","author":"Tarullj","year":"2009","journal-title":"J Clin Neuromuscul Dis"},{"key":"R57-14-20210206","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/mus.21779","article-title":"Muscle ultrasound quantifies the rate of reduction of muscle thickness in amyotrophic lateral sclerosis.","volume":"42","author":"Lee","year":"2010","journal-title":"Muscle Nerve"},{"key":"R58-14-20210206","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1136\/jnnp.2009.200519","article-title":"Muscle ultrasonography to predict survival in amyotrophic lateral sclerosis.","volume":"82","author":"Arts","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R59-14-20210206","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S1474-4422(08)70293-X","article-title":"Markers in amyotrophic lateral sclerosis.","volume":"8","author":"Turner","year":"2009","journal-title":"Lancet Neurol"},{"key":"R60-14-20210206","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1468-1331.2010.02951.x","article-title":"EFNS guidelines on the use of neuroimaging in the management of motor neuron diseases.","volume":"17","author":"Filippi","year":"2010","journal-title":"Eur J Neurol"},{"key":"R61-14-20210206","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/ana.10554","article-title":"GJ, Veldink JH, van der Tweel, et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis.","volume":"53","year":"2003","journal-title":"Ann Neurol"},{"key":"R62-14-20210206","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1080\/17482960802195632","article-title":"A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS.","volume":"9","author":"Gordon","year":"2008","journal-title":"Amyotroph Lateral Scler"},{"key":"R63-14-20210206","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.21620","article-title":"Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis.","volume":"66","author":"Piepers","year":"2009","journal-title":"Ann Neurol"},{"key":"R64-14-20210206","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1474-4422(10)70068-5","article-title":"Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.","volume":"9","author":"Aggarwal","year":"2010","journal-title":"Lancet Neurol"},{"key":"R65-14-20210206","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/ana.21743","article-title":"Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III.","volume":"66","author":"Kaufmann","year":"2009","journal-title":"Ann Neurol"},{"key":"R66-14-20210206","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3109\/17482960903307805","article-title":"A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis.","volume":"11","author":"Pascuzzi","year":"2010","journal-title":"Amyotroph Lateral Scler"},{"key":"R67-14-20210206","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/ana.22093","article-title":"Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect.","volume":"68","author":"Pioro","year":"2010","journal-title":"Ann Neurol"},{"key":"R68-14-20210206","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1136\/jnnp.2009.200642","article-title":"Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial.","volume":"81","author":"Weber","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R69-14-20210206","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3109\/17482968.2010.498521","article-title":"A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis.","volume":"11","author":"de Carvalho","year":"2010","journal-title":"Amyotroph Lateral Scler"},{"key":"R70-14-20210206","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1212\/WNL.0b013e3181ed9e7c","article-title":"Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial.","volume":"75","author":"Chio","year":"2010","journal-title":"Neurology"},{"key":"R71-14-20210206","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1136\/jnnp.2010.206680","article-title":"Home telemonitoring of non-invasive ventilation decreases healthcare utilization in a prospective controlled trial of ALS patients.","volume":"81","author":"Pinto","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R72-14-20210206","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.amjsurg.2008.11.008","article-title":"Amyotrophic lateral sclerosis: the Midwestern surgical experience with the diaphragm pacing stimulation system shows that general anesthesia can be safely performed.","volume":"197","author":"Onders","year":"2009","journal-title":"Am J Surg"}],"container-title":["Current Opinion in Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/WCO.0b013e32834916a9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T08:11:08Z","timestamp":1620979868000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00019052-201110000-00014"}},"subtitle":["an update"],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":68,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/wco.0b013e32834916a9","relation":{},"ISSN":["1350-7540"],"issn-type":[{"value":"1350-7540","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}